Tag: Obesity Treatment
-
Six New Weight Loss Drugs That Could Dithrone Ozempic
Introduction: The Ozempic Era and the Next Wave Ozempic and its GLP-1 peers transformed obesity and type 2 diabetes treatment by delivering meaningful weight loss beyond diet and exercise alone. As more patients seek effective options, researchers are racing to bring new therapies to market. Here are six promising weight loss drugs in late-stage development…
-
Rise of Off-Label Weight-Loss Injections in the UK: What the New Survey Reveals
UK Survey Highlights a Surge in Weight-Loss Injections A recent UK-wide survey has brought attention to a significant shift in how people are addressing obesity and weight management. The study found that at least 1.6 million residents of the United Kingdom used weight-loss injections over the past year. While this demonstrates a growing interest in…
-
NHS Fat Jabs: Why Real Changes Matter for Lasting Success
The promise of fat jabs Weight loss injections—often referred to as GLP-1 therapies—have become a focal point in public health discussions. Proponents say these medicines can help people lose significant weight, improve metabolic health, and reduce obesity-related risks. In NHS settings, the question isn’t whether the injections can work in the lab, but whether they…
-
Novo Nordisk’s Wegovy Pill: Broad U.S. Rollout of Oral GLP-1 for Weight Loss
Overview: Wegovy’s Evolution from Injection to an Oral Pill Novo Nordisk has expanded access to Wegovy, the popular GLP-1-based weight loss therapy, with the introduction of a pill form. Semaglutide, the active ingredient, is delivered as tablets (25 mg) that are designed to be taken daily. This marks a significant shift for patients who preferred…
-
Novo Nordisk’s Wegovy®: The First Oral GLP-1 Weight-Loss Pill Reaching Broad U.S. Availability
Introduction: A Milestone in Weight Management New options in weight management are always welcome for adults struggling with obesity and related health risks. Novo Nordisk has expanded access to Wegovy® (semaglutide) in an oral tablet form, marking the first and, so far, only oral GLP-1 therapy specifically approved for weight loss in adults. This shift…
-
What to Expect from 2026 in Science, Arts, Politics and Society
Overview: A year of rapid change across multiple fronts As 2026 unfolds, global headlines point to a year of rapid innovation and evolving social norms. From medical breakthroughs in obesity treatment to shifts in political landscapes and transformative trends in the arts, the year ahead is likely to redefine everyday life for millions. This overview…
-
India’s Doctors Sound Alarm Over Boom in Availability of Weight Loss Injections
Unregulated Rush for Weight Loss Injections India’s medical community is sounding the alarm over a rapidly expanding market for weight loss injections. While appetite-suppressing drugs have shown potential in clinical settings, doctors warn that an unregulated boom risks patient safety, long-term health consequences, and the misapplication of these treatments as a quick fix for obesity…
-
Wegovy Advances to PBS Listing: Semaglutide for Obesity and Heart Disease
Wegovy Moves Closer to PBS Listing Semaglutide, sold under the brand Wegovy, is nearing a pivotal milestone in Australia’s healthcare system. After preliminary recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC), Wegovy could soon be available on the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease who also have obesity. This potential PBS…
-
Postpartum GLP-1 Drugs Use Among New Mothers Surges, Study Finds
Overview: A new trend in postpartum care Researchers from Denmark have identified a notable shift in how some women manage weight after pregnancy. The study, which tracked medication use among postpartum women, found a sharp increase in prescriptions for GLP-1 receptor agonists—commonly known as weight‑loss drugs such as Ozempic and Wegovy—beginning shortly after childbirth. This…
-
GLP-1 Medications and Pregnancy: Interpreting Early Signals and Risks
Understanding GLP-1 Medications and Pregnancy GLP-1 receptor agonists, such as Ozempic (semaglutide), are widely prescribed for type 2 diabetes and some cases of obesity treatment. They work by mimicking an incretin hormone that helps regulate blood sugar and appetite. When considering pregnancy, however, medical guidance has historically recommended avoiding GLP-1 medications because of potential risks…